Nudix Hydrolase 15 (NUDT15) Gene Mutation Analysis
The NUDT15 gene is located on the long (q) arm of chromosome 13 at position 14.2. This gene encodes Nudix hydrolase 15 proteins, which belong to a family of enzymes that degrade oxidized nucleoside diphosphates, including 8-oxo-dGTP. These oxidized bases, which can result from the action of reactive oxygen species, induce base mispairing during nucleic acid synthesis that leads to translational errors. In addition, the NUDT15 enzyme demonstrates a strong preference for inactivating thiopurine metabolites over oxo-dGTP. Thiopurine prodrugs, which are used as anticancer and immunosuppressive agents, are converted into activated thioguanosine triphosphate (TGTP) and TdGTP metabolites. Through the hydrolysis of TGTP, NUDT15 enzyme may participate in the catabolism of thiopurine drugs.
Mutations in NUDT15 gene are associated with an accumulation of cytotoxic metabolites in patients treated with thiopurines (mercaptopurine, thioguanine, and azathioprine), causing an increased risk of drug-related toxicity with standard dosing. The disorder is termed ‘Thiopurines, poor metabolism of, 2’ (also known as NUDT15 deficiency), and is associated with severe hematopoietic toxicity. The NUDT15 deficiency trait follows an additive genetic mode of inheritance, with the severity of the phenotype proportional to the cumulative number of risk alleles in NUDT15.
Most common variants impacting the enzyme function are as follow: *2 variatn with no activity, *3A variant with no activity, *3B variant with no activity, *3C variant with no activity, *4 variant with no activity, *5 with no activity, *8 variant with reduced activity, *12 variant with reduced activity. Variant *1/*1 is a wild type with normal function.
- Toxicity evaluation for thiopurine drugs (6-mercaptopurine, 6-thioguanine, and azathioprine) used in leukemia, autoimmune diseases and organ transplant
- For the clinical management and therapy of cancer patients
Most common NUDT15 Genotype with impact on enzyme function and high toxicity when treated with thiopurines:
*2 variant with no activity
*3A variant with no activity
*3B variant with no activity
*3C variant with no activity
*4 variant with no activity
*5 variant with no activity
*8 variant with reduced activity
*12 variant with reduced activity
NUDT15 Genotype: *1/*1
NUDT15 Phenotype: Normal metabolizer
Normal toxicity risk when treated with thiopurines.
Whole Blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unacceptable
- J Mol Diagn. 2022 Oct;24(10):1051-1063. [PMID: 35931343]
- Pediatr Res. 2020 Mar 27. doi: 10.1038/s41390-020-0868-8. [PMID: 32221476]
- Front Pharmacol. 2019 Apr 9;10:346. [PMID: 31024313]
- Nat Genet. 2016: 367-73. [PMID: 26878724]
- Nat Genet. 2014;46: 1017-20. [PMID: 25108385]
- J Biol Chem. 2012;287: 21541-9. [PMID: 22556419]
- Nucleic Acids Res. 2011;39:8972-83. [PMID: 21768126]
- Gene, available at: https://www.ncbi.nlm.nih.gov/gene/55270